1-3 of 3
Lijuan Kang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Open Access
Clinical Trials & Observations
Ajai Chari, Niels W.C.J. van de Donk, Bhagirathbhai Dholaria, Katja C Weisel, Maria-Victoria Mateos, Hartmut Goldschmidt, Tom G Martin, Daniel Morillo, Donna Reece, Paula Rodriguez-Otero, Manisha Bhutani, Anita D'Souza, Albert Oriol, Laura Rosiñol, Nizar J. Bahlis, Deeksha Vishwamitra, Sheri Skerget, Raluca I. Verona, Kalpana K Bakshi, Lijuan Kang, Thomas J Prior, Lien Vandenberk, Jaszianne Tolbert, Sangmin Lee, Damiette Smit, Ralph Wäsch
Journal: Blood
Blood blood.2025029360.
https://doi.org/10.1182/blood.2025029360
Published: 2025
Includes: Supplemental data
Journal Articles

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Free
Anita D'Souza, Luciano J. Costa, Jesús F. San-Miguel, Jesus G Berdeja, Daniel Morillo Giles, Cyrille Touzeau, John T McKay, Bhagirathbhai Dholaria, Thomas G Martin, Aurore Perrot, Albert Oriol, Anna Sureda Balari, Thomas Prior, Debopriya Ghosh, Lijuan Kang, Julie S Larsen, Hein Ludlage, Lien Vandenberk, Lingling Chen, Bas D Koster, Weili Sun, Rachel Kobos, Emma Searle, Jeffrey V Matous, Ajai Chari, Tobias Kampfenkel
Journal: Blood
Blood (2024) 144 (Supplement 1): 495.
https://doi.org/10.1182/blood-2024-200181
Published: 2024
Journal Articles

Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results

Free
Robert Rifkin, Henning Schade, Gary Simmons, Christopher Yasenchak, Jessica Fowler, Thomas S. Lin, Lijuan Kang, Weiming Xu
Journal: Blood
Blood (2024) 144 (Supplement 1): 4753.
https://doi.org/10.1182/blood-2024-207295
Published: 2024